JP2009533367A5 - - Google Patents

Download PDF

Info

Publication number
JP2009533367A5
JP2009533367A5 JP2009504628A JP2009504628A JP2009533367A5 JP 2009533367 A5 JP2009533367 A5 JP 2009533367A5 JP 2009504628 A JP2009504628 A JP 2009504628A JP 2009504628 A JP2009504628 A JP 2009504628A JP 2009533367 A5 JP2009533367 A5 JP 2009533367A5
Authority
JP
Japan
Prior art keywords
antibody
antibody according
amount
less
acc2795
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009504628A
Other languages
English (en)
Japanese (ja)
Other versions
JP4718634B2 (ja
JP2009533367A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2007/003165 external-priority patent/WO2007115814A2/en
Publication of JP2009533367A publication Critical patent/JP2009533367A/ja
Publication of JP2009533367A5 publication Critical patent/JP2009533367A5/ja
Application granted granted Critical
Publication of JP4718634B2 publication Critical patent/JP4718634B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009504628A 2006-04-11 2007-04-10 インスリン様増殖因子i受容体及びその使用 Active JP4718634B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06007571 2006-04-11
EP06007571.0 2006-04-11
PCT/EP2007/003165 WO2007115814A2 (en) 2006-04-11 2007-04-10 Antibodies against insulin-like growth factor i receptor and uses thereof

Publications (3)

Publication Number Publication Date
JP2009533367A JP2009533367A (ja) 2009-09-17
JP2009533367A5 true JP2009533367A5 (https=) 2010-11-11
JP4718634B2 JP4718634B2 (ja) 2011-07-06

Family

ID=36940705

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009504628A Active JP4718634B2 (ja) 2006-04-11 2007-04-10 インスリン様増殖因子i受容体及びその使用

Country Status (20)

Country Link
US (1) US20080014203A1 (https=)
EP (2) EP2007810B1 (https=)
JP (1) JP4718634B2 (https=)
KR (2) KR101276513B1 (https=)
CN (1) CN101421305B (https=)
AR (1) AR060592A1 (https=)
AU (1) AU2007236199B2 (https=)
BR (1) BRPI0710185B8 (https=)
CA (2) CA2647181C (https=)
CR (1) CR10301A (https=)
EC (1) ECSP088816A (https=)
ES (1) ES2403075T3 (https=)
IL (1) IL194397A (https=)
MX (1) MX2008012950A (https=)
NO (1) NO20084082L (https=)
NZ (1) NZ571414A (https=)
RU (1) RU2541765C2 (https=)
UA (1) UA95284C2 (https=)
WO (1) WO2007115814A2 (https=)
ZA (1) ZA200808597B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
US20090068110A1 (en) * 2006-12-22 2009-03-12 Genentech, Inc. Antibodies to insulin-like growth factor receptor
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
CN101903401B (zh) 2007-12-21 2013-06-05 罗切格利卡特公司 抗体的稳定性试验
NZ592151A (en) 2008-12-12 2012-10-26 Boehringer Ingelheim Int Anti-igf antibodies
WO2010112194A1 (en) * 2009-04-02 2010-10-07 F. Hoffmann-La Roche Ag Antigen-binding polypeptides and multispecific antibodies comprising them
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
BRPI1010068A2 (pt) 2009-07-24 2016-03-15 Hoffmann La Roche "sistema agitador, dispositivo, método para cultivo de células animais, método para produzir um polipeptídeo, uso de um sistema agitador e dispositivos para cultivar células animais"
WO2011044336A2 (en) * 2009-10-07 2011-04-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human domain antibodies against components of the human insulin-like growth factor (igf) system
WO2011051231A1 (en) 2009-10-26 2011-05-05 F. Hoffmann-La Roche Ag Method for the production of a glycosylated immunoglobulin
US20110200595A1 (en) 2010-02-18 2011-08-18 Roche Glycart TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
WO2011135040A1 (en) 2010-04-30 2011-11-03 F. Hoffmann-La Roche Ag Fluorescent antibody fusion protein, its production and use
RU2591523C2 (ru) 2010-11-05 2016-07-20 Ф. Хоффманн-Ля Рош Аг Оптимизированный метод захвата антител хроматографией смешанного типа
EA201400046A1 (ru) 2011-06-22 2014-07-30 Ф. Хоффманн-Ля Рош Аг Удаление клеток-мишеней с помощью циркулирующих вирусспецифических цитотоксических т-клеток с использованием содержащих гкгс класса i комплексов
RU2502798C2 (ru) * 2012-02-22 2013-12-27 Общество с ограниченной ответственностью "Фармако Биотех" КЛЕТОЧНАЯ ЛИНИЯ huFSHIK, СЕКРЕТИРУЮЩАЯ РЕКОМБИНАНТНЫЙ ЧЕЛОВЕЧЕСКИЙ ФСГ
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
US20150259430A1 (en) 2012-11-05 2015-09-17 Mab Discovery Gmbh Method for the production of multispecific antibodies
CA2889788A1 (en) 2012-12-21 2014-06-26 F. Hoffmann-La Roche Ag Disulfide-linked multivalent mhc class i comprising multi-function proteins
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
WO2021119234A1 (en) * 2019-12-10 2021-06-17 Horizon Pharma Ireland Ltd. Glycosylated antibodies against insulin-like growth factor i receptor and uses thereof
CN119792512A (zh) 2020-10-14 2025-04-11 维里迪安治疗公司 用于治疗甲状腺眼病的组合物和方法
TW202320850A (zh) 2021-08-10 2023-06-01 美商維里迪恩醫療股份有限公司 用於治療甲狀腺眼病之組合物、劑量及方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US5204244A (en) * 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) * 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
US5610297A (en) * 1991-12-27 1997-03-11 Georgia Tech Research Corp. Peptides ketoamides
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
EP1176195B1 (en) * 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US20030165502A1 (en) * 2000-06-13 2003-09-04 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
US7553485B2 (en) * 2002-01-18 2009-06-30 Pierre Fabre Medicament Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
US7217796B2 (en) * 2002-05-24 2007-05-15 Schering Corporation Neutralizing human anti-IGFR antibody
EP1613658B1 (en) * 2003-04-02 2012-03-14 F. Hoffmann-La Roche AG Antibodies against insulin-like growth factor i receptor and uses thereof
AR046071A1 (es) * 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
EP1666501A4 (en) * 2003-08-11 2008-12-24 Chugai Pharmaceutical Co Ltd Sugar chain-modified anti-HM1.24 antibody
EP1693069B1 (en) * 2003-10-10 2013-07-24 Chugai Seiyaku Kabushiki Kaisha Remedy for solid tumor

Similar Documents

Publication Publication Date Title
JP2009533367A5 (https=)
AU2013229786B2 (en) Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
Strohl Structure and function of therapeutic antibodies approved by the US FDA in 2023
JP6282745B2 (ja) 修飾抗上皮成長因子受容体抗体およびその使用法
JP2009114201A5 (https=)
CN117222663A (zh) 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法
JP2017071606A5 (https=)
JP2009532336A5 (https=)
WO2017161206A1 (en) Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
PT2576618T (pt) Anticorpos contra gdf8 humano
JP2019527194A5 (https=)
JP2025069249A (ja) 多重特異性抗体およびその使用
CA3158579A1 (en) Heavy chain antibodies binding to cd38
JP2018512402A5 (https=)
JP2020527152A5 (https=)
WO2018183366A1 (en) Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
IT201800000534A1 (it) Procedimenti per la promozione della crescita cellulare degli isolotti pancreatici.
JP2023537078A (ja) COVID-19を治療及び防止するためのSARS-CoV-2抗体
TW202124432A (zh) 使用pd-1軸抑制劑及抗骨膜蛋白抗體治療癌症之方法
CN115957321A (zh) 一种抗her2抗体在制备治疗癌症的药物中的用途
US20250257141A1 (en) Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist
JP7668943B2 (ja) 多重特異性抗体およびその使用
US20220218838A1 (en) Adc for a treatment concomitant with or subsequent to docetaxel
WO2025072516A1 (en) Methods of reducing weight loss using anti-gdf15 antibodies
JP2025036273A (ja) 多重特異性抗体およびその使用